NIR-II-activated supramolecular LDH nanoarchitecture integrated with 3D-printed bioactive glass for hypoxia-resistant photodynamic osteosarcoma therapy and bone regeneration
A novel functionalized 3D-printed scaffold with NIR-II responsiveness (BGS/I-LDH@MgO2), designed to simultaneously address the dual needs of inhibiting osteosarcoma recurrence and promoting bone regeneration, demonstrates excellent anti-tumor and osteogenic properties.
Abstract
The clinical management of osteosarcoma faces critical challenges, including postoperative recurrence and metastasis of residual tumor cells, chemotherapy resistance, and impaired self-repair capacity due to extensive bone defects following tumor resection. Herein, we develop a novel functionalized 3D-printed scaffold with NIR-II responsiveness (BGS/I-LDH@MgO2), designed to simultaneously address the dual needs of inhibiting osteosarcoma recurrence and promoting bone regeneration. This scaffold consists of 3D-printed bioactive glass scaffold (BGS) and MgO2-modified ZnAl-layered double hydroxides (ZnAl-LDHs) intercalated with 5-iodo-isophthalic acid (I-IPA). Under NIR-II irradiation, the scaffold effectively triggers a photodynamic therapy (PDT) effect to eliminate osteosarcoma cells. Notably, the incorporation of MgO2 enables oxygen release within the tumor microenvironment, alleviating hypoxia and enhancing PDT efficacy for superior antitumor performance. Furthermore, the degradation of ZnAl-LDHs and MgO2 releases Mg2+ and Zn2+ ions and generates a mildly alkaline microenvironment, which collectively facilitate the osteogenic differentiation of bone marrow mesenchymal stem cells and accelerate the process of bone healing. This functionalized 3D-printed scaffold demonstrates excellent anti-tumor and osteogenic properties, showing great promise for the treatment of osteosarcoma-associated bone defects.
A 3D-printed sodium alginate/GelMA hydrogel scaffold is engineered to remodel the local microenvironment for simultaneous tumor ablation and bone repair, aiming to overcome the persistent challenge of functionally modifying hydrogel scaffolds to achieve both effective tumor eradication and bone regeneration.
Jia-Chen He, Jianjun Wu, Lin Wang et al.· Advanced Composites and Hybr...· 0 citations
In vivo validation confirms a 90% tumor inhibition rate alongside robust biosafety, offering a novel self-powered paradigm for integrated therapy and repair post-osteosarcoma surgery.
Botao Lu, Zeyu Chen, Shichao Yan et al.· Biomaterials· 0 citations
A NIR-II-responsive multifunctional hydrogel platform that couples infection eradication with microenvironment remodeling to drive bone regeneration, providing a promising strategy for treating infected bone defects is established.
Kai-Wen Chang, Pei-Yu Lin, Ke Xue et al.· Biomaterials Advances· 0 citations
The postoperative repair of bone tumors remains a significant clinical challenge requiring urgent solutions, and this holds particularly true for regenerating large bone defects, completely removing residual tumor cells, and effectively preventing and controlling postoperative infections. The efficacy of traditional si...
Liu Yang, Kenan Sun, Shihao Deng et al.· Journal of Biological Engine...· 0 citations
In vivo antitumor studies demonstrate that PFD released in situ remodels TME by downregulating hyaluronic acid and type I collagen expression, normalizing tumor vasculature, improving intratumoral oxygen perfusion and contributing to amplified PDT.
Jingjing Jiao, Yibing Wang, Kangkang Huang et al.· Colloids and Surfaces B: Bio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.